PT  - JOURNAL ARTICLE
AU  - Vicky Brocklebank
AU  - David Kavanagh
TI  - Protecting the kidney from complement: atypical haemolytic uraemic syndrome
AID  - 10.7861/clinmedicine.14-6-s89
DP  - 2014 Dec 01
TA  - Clinical Medicine
PG  - s89--s94
VI  - 14
IP  - Suppl 6
4099  - http://www.rcpjournals.org/content/14/Suppl_6/s89.short
4100  - http://www.rcpjournals.org/content/14/Suppl_6/s89.full
SO  - Clin Med2014 Dec 01; 14
AB  - Atypical haemolytic uraemic syndrome is a thrombotic microangiopathy with a predominant renal phenotype. Research developments in the last 15 years have led to the elucidation of the role of complement over activation in the pathogenesis of the disease. This was to lead to the successful introduction of targeted pharmacological therapy, in the form of the complement inhibitor, eculizumab.